SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Apricus Biosciences
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: mokelumne river who wrote (1310)6/17/2015 4:33:48 PM
From: eico20  Read Replies (1) of 2026
 
good thinking James, it's interesting that Sarissa owns RPRX as well, Femprox would have to bring in $25M in up front cash, which is possible but Flib. approval in Aug has to happen first and the labeling on Flib. could be a factor as well, and then resumption of talks on Femprox, so that could take time. More Up fronts on Vitaros I agree won't be much, not sure on Rayva, buts it's only in PH2 so you are probably right on that as well.

But if Vitaros starts taking off they could finance Fis. PH3 trials with debt.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News